6.
Gronich J, Bonventre J, Nemenoff R
. Identification and characterization of a hormonally regulated form of phospholipase A2 in rat renal mesangial cells. J Biol Chem. 1988; 263(32):16645-51.
View
7.
Goddard T, Huang C, Meng E, Pettersen E, Couch G, Morris J
. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci. 2017; 27(1):14-25.
PMC: 5734306.
DOI: 10.1002/pro.3235.
View
8.
Leek J, Johnson W, Parker H, Jaffe A, Storey J
. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28(6):882-3.
PMC: 3307112.
DOI: 10.1093/bioinformatics/bts034.
View
9.
Xue D, Xu J, McGuire S, Devitre D, Sun G
. Studies on the cytosolic phospholipase A2 in immortalized astrocytes (DITNC) revealed new properties of the calcium ionophore, A23187. Neurochem Res. 1999; 24(10):1285-91.
DOI: 10.1023/a:1020981224876.
View
10.
Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A
. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?. Int Rev Neurobiol. 2007; 82:235-46.
DOI: 10.1016/S0074-7742(07)82012-5.
View
11.
Lin L, Lin A, Knopf J
. Cytosolic phospholipase A2 is coupled to hormonally regulated release of arachidonic acid. Proc Natl Acad Sci U S A. 1992; 89(13):6147-51.
PMC: 402139.
DOI: 10.1073/pnas.89.13.6147.
View
12.
Johnson W, Li C, Rabinovic A
. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2006; 8(1):118-27.
DOI: 10.1093/biostatistics/kxj037.
View
13.
Gijon M, Spencer D, Siddiqi A, Bonventre J, Leslie C
. Cytosolic phospholipase A2 is required for macrophage arachidonic acid release by agonists that Do and Do not mobilize calcium. Novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A2 regulation. J Biol Chem. 2000; 275(26):20146-56.
DOI: 10.1074/jbc.M908941199.
View
14.
Thakur P, Nehru B
. Inhibition of neuroinflammation and mitochondrial dysfunctions by carbenoxolone in the rotenone model of Parkinson's disease. Mol Neurobiol. 2014; 51(1):209-19.
DOI: 10.1007/s12035-014-8769-7.
View
15.
Humphrey W, Dalke A, Schulten K
. VMD: visual molecular dynamics. J Mol Graph. 1996; 14(1):33-8, 27-8.
DOI: 10.1016/0263-7855(96)00018-5.
View
16.
Qian L, Flood P, Hong J
. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J Neural Transm (Vienna). 2010; 117(8):971-9.
PMC: 3392895.
DOI: 10.1007/s00702-010-0428-1.
View
17.
Gijon M, Spencer D, Kaiser A, Leslie C
. Role of phosphorylation sites and the C2 domain in regulation of cytosolic phospholipase A2. J Cell Biol. 1999; 145(6):1219-32.
PMC: 2133140.
DOI: 10.1083/jcb.145.6.1219.
View
18.
Binukumar B, Gupta N, Sunkaria A, Kandimalla R, Wani W, Sharma D
. Protective efficacy of coenzyme Q10 against DDVP-induced cognitive impairments and neurodegeneration in rats. Neurotox Res. 2011; 21(4):345-57.
DOI: 10.1007/s12640-011-9289-0.
View
19.
Zheng B, Liao Z, Locascio J, Lesniak K, Roderick S, Watt M
. PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med. 2010; 2(52):52ra73.
PMC: 3129986.
DOI: 10.1126/scitranslmed.3001059.
View
20.
Shukla V, Seo J, Binukumar B, Amin N, Reddy P, Grant P
. TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice. J Alzheimers Dis. 2017; 56(1):335-349.
PMC: 10020940.
DOI: 10.3233/JAD-160916.
View